Similar articles

• Eltrombopag in chronic idiopathic thrombocytopenic purpura.

  Panzer S, Pabinger I. Panzer S, et al. Lancet. 2009 Feb 21;373(9664):607-8. doi: 10.1016/S0140-6736(09)60377-9. Lancet. 2009. PMID: 19231614 No abstract available.
• Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

  Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Bussel JB, et al. Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5. Lancet. 2009. PMID: 19231632 Clinical Trial.
• Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.

  Tarantino MD, Fogarty PF, Shah P, Brainsky A. Tarantino MD, et al. Platelets. 2015;26(1):93-6. doi: 10.3109/09537104.2013.870333. Epub 2014 Jan 16. Platelets. 2015. PMID: 24433306
• Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.

  Altomare I, Wasser J, Pullarkat V. Altomare I, et al. Am J Hematol. 2012 Oct;87(10):984-7. doi: 10.1002/ajh.23275. Epub 2012 Jun 22. Am J Hematol. 2012. PMID: 22729832 Review.
• Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.

  Stasi R. Stasi R. Expert Rev Hematol. 2008 Dec;1(2):145-52. doi: 10.1586/17474086.1.2.145. Expert Rev Hematol. 2008. PMID: 21082919 Review.